NICE backs KEYTRUDA combination for advanced endometrial cancer
New first-line option for patients with pMMR and dMMR tumours in England New first-line option for patients with pMMR and dMMR tumours in England
Previous Post
FDA expands AVTOZMA IV approval to include cytokine release syndrome
Next Post
GPs struggle with workload more than other doctors, finds GMC
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago